Immunocore Ltd
Clinical trials sponsored by Immunocore Ltd, explained in plain language.
-
New drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug, IMC-R117C, for people with advanced colorectal, esophageal, stomach, or ovarian cancers that have a specific protein (PIWIL1) and a certain immune type (HLA-A*02:01). The goal is to see if the drug is safe and can shrink or control tumors. About 600 p…
Phase: PHASE1, PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 26, 2026 03:53 UTC
-
New combo therapy aims to extend life in advanced melanoma
Disease control Recruiting nowThis study tests whether the drug tebentafusp, alone or combined with pembrolizumab, helps people with advanced melanoma live longer compared to standard treatments. It includes about 540 adults with a specific genetic marker (HLA-A*02:01) whose melanoma has worsened after prior …
Phase: PHASE3 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 26, 2026 03:50 UTC
-
New combo therapy aims to boost immune attack on advanced melanoma
Disease control Recruiting nowThis phase 3 trial tests whether adding an experimental drug (IMC-F106C) to the standard immunotherapy nivolumab works better than nivolumab alone for people with advanced melanoma. About 680 adults with a specific genetic marker (HLA-A*02:01) who have not had prior treatment wil…
Phase: PHASE3 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 26, 2026 03:45 UTC
-
New immune drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug, IMC-P115C, designed to help the immune system find and attack cancer cells that have a protein called PRAME. It is for people with advanced solid tumors who have a specific genetic marker (HLA-A*02:01) and have tried other treatments. The …
Phase: PHASE1 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated May 15, 2026 11:55 UTC